Endometrial cancer with concomitant endometriosis is highly associated with ovarian endometrioid carcinoma: a retrospective cohort study

Aya Ishizaka1, Ayumi Taguchi1*, Tetsushi Tsuruga1, Marie Maruyama1, Akira Kawata1, Yuichiro Miyamoto1, Michihiro Tanikawa1, Masako Ikemura2, Kenbun Sone1, Mayuyo Mori1, Kaori Koga1, Tetsuo Ushiku2, Katsutoshi Oda3 and Yutaka Osuga1

Abstract

Background: Endometriosis is assumed to be involved in ovarian cancer development, which is called endometriosis-associated ovarian cancer (EAOC). Uterine endometrial cells may be the cell of origin of EAOC. Accumulated carcinogenic changes in the uterine endometrial cells may increase the risk of developing EAOC. To further understand the pathogenesis of EAOCs, we focused on the clinicopathological characteristics of EAOCs in endometrial cancer patients with concomitant endometriosis.

Methods: We retrospectively reviewed 376 patients who were surgically treated for stage I–III endometrial cancer. Clinicopathological characteristics were compared between patients with and without endometriosis. Furthermore, the incidence of simultaneous endometrial and ovarian cancer (SEOC) and the histological characteristics of SEOC were compared between the two groups.

Results: Among 376 patients with endometrial cancer, 51 had concomitant endometriosis. Patients with endometriosis were significantly younger and more frequently had endometrioid G1/G2 tumors than those without endometriosis. The incidence of SEOCs was significantly higher in endometrial cancer patients with endometriosis than those without it ($p<0.0001$); notably, 12 of 51 endometrial cancer patients with endometriosis (24%) had SEOCs. All of the ovarian cancers in endometrial cancer patients with endometriosis were endometrioid carcinomas. Moreover, even in those without endometriosis, endometrioid carcinoma was the most common histological type of SEOC.

Conclusion: We revealed that endometrial cancer patients with endometriosis had a high probability of SEOC and that endometrioid carcinoma was the most common histological subtype of SEOC regardless of the presence of endometriosis. For patients with endometrial cancer and endometriosis, careful examination of ovarian endometriotic lesions may be important to detect EAOCs.

Keywords: Endometriosis, Endometrial cancer, Ovarian cancer, Endometrioid carcinoma

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
that endometriosis is caused by the regurgitation of the tubal and uterine epithelium through the fallopian tubes into the pelvic cavity [2]. Patients with endometriosis have a higher risk of developing ovarian endometrioid or clear cell carcinoma than those without endometriosis [3–7]. Based on epidemiological findings, endometriosis is considered the origin of ovarian endometrioid and clear cell carcinoma [8–10]. In addition, genomic studies have demonstrated that cancer-related genomic alterations are present in some endometriotic lesions [4, 11–16]. Moreover, a previous report showed that shared genomic alterations were detected in both clear cell carcinoma and endometriotic sites [17–20]. These genomic findings support the hypothesis that endometriosis is the origin of ovarian endometrioid and clear cell carcinoma.

The pathogenesis of endometriosis is considered to involve regurgitation of the uterine endometrium. Recent genomic research has shown that endometriosis-associated ovarian cancers (EOCs) share a common cell of origin with the uterine endometrium [5, 14]. Because the carcinogenesis of EOCs is a multi-stage process [14], ovarian endometrioma derived from an endometrium with carcinogenic changes might have a higher chance to develop EOCs. To further understand the pathogenesis of EOCs, we focused on the clinicopathological characteristics of EOCs in endometrial cancer (EC) patients with endometriosis.

**Methods**

**Patients**

This study was approved by the Research Ethics Committee of the Faculty of Medicine of the University of Tokyo (approval number: 3084–7, G0683). We retrospectively reviewed 376 patients with stage I–III EC who underwent surgery with curative intent at the University of Tokyo Hospital between 2007 and 2015, as previously described [21]. Clinical data, such as age, body mass index (BMI), and parity were reviewed. The presence of endometriosis and other pathological features, such as histological grade, pathological stage, myometrial invasion, lymphatic vessel invasion, blood vessel invasion, and lymph node metastasis, were obtained from pathological records. Endometriosis was defined as pathologically detected endometriosis in the resected specimen obtained during surgery for EC. EC patients were divided into two groups according to the presence of endometriosis. Patients with adenomyosis without endometriotic lesions outside the uterus were classified into EC patients without endometriosis. Follow-up information was obtained in August 2021. The diagnosis of simultaneous endometrial and ovarian cancer (SEOC) was based on the criteria proposed by Scully and Young [22]. In this study, other than ovarian cancer, one case each of fallopian tube cancer and peritoneal cancer was included in SEOC.

**Statistical analysis**

Clinicopathological data were compared by Wilcoxon analysis for continuous variables and by chi-square test for categorical variables in EC patients with and without endometriosis and in EC patients with and without SEOC. In order to investigate the risk factors of SEOC, a multivariate logistic regression analysis was conducted using the following factors as covariates: age, histology of endometrial cancer, myometrial invasion, and presence of endometriosis. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and analyzed using the log-rank test according to the presence of endometriosis. PFS was calculated from the date of surgery to the date of disease progression or death from any cause. OS was calculated from the date of surgery to the date of death from any cause.

All statistical analyses were performed using JMP Pro version 14.1.0 (SAS Institute, Cary, NC, USA). Differences were considered statistically significant at \( p < 0.05 \).

**Results**

**Clinicopathological characteristics of EC patients with endometriosis**

Among the 376 patients with EC, 51 had endometriosis. Among them, 21 patients had ovarian endometrioma and the remaining 30 patients had deep endometriosis and/or endometriosis at the surface of the ovaries, the surface of the uterus, and/or peritoneum. The clinicopathological characteristics of patients with EC according to the presence of endometriosis are summarized in Table 1. Patients with endometriosis were significantly younger (\( p = 0.012 \)) and more frequently had endometrioid G1/G2 tumors than those without endometriosis (\( p = 0.036 \)). There were no significant differences in PFS and OS between EC patients with and without endometriosis (Additional file 1: Fig. S1A and B).

**EC patients with endometriosis were frequently accompanied by ovarian carcinoma**

Out of the 376 total EC patients, SEOCs were found in 21 (5.6%). Patients with SEOC were significantly younger than those without it (\( p = 0.015 \)) and all of them had endometrioid G1/G2 EC (Table 2). When these patients were analyzed based on the presence or absence of endometriosis, the incidence of SEOCs was significantly higher in EC patients with endometriosis than in those without it (Fig. 1A, \( p < 0.0001 \)), with 12 of 51 (24%) EC patients with endometriosis having SEOCs. Furthermore, when endometriosis was analyzed separately by the presence or absence of ovarian
Table 1  Patients’ characteristics according to the presence of endometriosis

| Parameters                        | Endometriosis + (n = 51) | Endometriosis − (n = 325) | p-values |
|----------------------------------|--------------------------|---------------------------|----------|
| Age at surgery, years, median (range) | 52.6 (36–78)            | 56.8 (23–88)              | 0.012*   |
| BMI, median (range)              | 24.8 (17.2–42.8)        | 24.2 (14.7–55.7)          | 0.761a   |
| Parity (%)                       |                          |                           |          |
| 0                                | 27 (53)                  | 138 (42)                  |          |
| ≥ 1                              | 24 (47)                  | 187 (58)                  | 0.162b   |
| T stage (%)                      |                          |                           |          |
| pT1                              | 44 (86)                  | 256 (79)                  |          |
| pT2                              | 4 (7.8)                  | 34 (10)                   |          |
| pT3                              | 3 (5.9)                  | 35 (11)                   |          |
| Histology of endometrial cancer (%)|                          |                           |          |
| EM G1 or G2                      | 46 (90)                  | 255 (78)                  |          |
| EM G3 or others                  | 5 (9.8)                  | 70 (22)                   |          |
| LVI (%)                          | 9 (18)                   | 73 (22)                   |          |
| BVI (%)                          | 7 (14)                   | 80 (25)                   |          |
| Myometrial invasion (%)          |                          |                           |          |
| < 1/2                            | 37 (73)                  | 205 (63)                  | 0.181b   |
| ≥ 1/2                            | 14 (27)                  | 120 (37)                  |          |
| LNM-positive (%)                 | 7 (14)                   | 42 (13)                   | 0.875b   |

BMI: Body mass index; LVI: Lymphatic vessel invasion; BVI: Blood vessel invasion; EM G1, 2, 3: Endometrioid carcinoma grade 1, 2, 3; LNM: Lymph node metastasis

* Statistically significant; aWilcoxon analysis; bChi-square test

Table 2  Patients’ characteristics according to the presence of SEOC

| Parameters                        | EC patients with SEOC (n = 21) | EC patients without SEOC (n = 355) | p-values |
|----------------------------------|---------------------------------|------------------------------------|----------|
| Age at surgery, years, median (range) | 50.6 (39–70)                  | 56.5 (23–88)                      | 0.0189a* |
| BMI, median (range)              | 23.6 (17.2–34.9)              | 24.3 (14.8–55.7)                  | 0.411a   |
| Parity (%)                       |                                |                                    |          |
| 0                                | 11 (52%)                       | 154 (43%)                         | 0.421b   |
| ≥ 1                              | 10 (48%)                       | 201 (57%)                         |          |
| T stage (%)                      |                                |                                    |          |
| pT1                              | 16 (76%)                       | 284 (80%)                         | 0.328b   |
| pT2                              | 4 (19%)                        | 34 (9.6%)                         |          |
| pT3                              | 1 (4.7%)                       | 37 (10.4%)                        |          |
| Histology of endometrial cancer (%)|                                 |                                    |          |
| EM G1 or G2                      | 21 (100%)                      | 280 (79%)                         |          |
| EM G3 or others                  | 0 (0.0%)                       | 75 (21%)                          |          |
| LVI (%)                          | 2 (9.5%)                       | 80 (23%)                          | 0.126b   |
| BVI (%)                          | 3 (14%)                        | 84 (24%)                          | 0.297b   |
| Myometrial invasion (%)          |                                |                                    |          |
| < 1/2                            | 18 (86%)                       | 224 (63%)                         | 0.016b*  |
| ≥ 1/2                            | 3 (14%)                        | 131 (36%)                         |          |
| LNM-positive (%)                 | 1 (4.7%)                       | 48 (13%)                          | 0.193b   |
| Presence of endometriosis (%)    | 12 (57%)                       | 39 (11%)                          | <0.0001b*|

SEOC: Simultaneous endometrial and ovarian cancer; EC: Endometrial cancer; BMI: Body mass index; LVI: Lymphatic vessel invasion; BVI: Blood vessel invasion; EM G1, 2, 3: Endometrioid carcinoma grade 1, 2, 3; LNM: Lymph node metastasis

* Statistically significant; aWilcoxon analysis; bChi-square test
endometrioma (regardless of the presence of other types of endometriosis), 10 (47%) EC patients with ovarian endometrioma had SEOCs, while only two (6.6%) without endometrioma had SEOCs (Fig. 1B). We subsequently conducted a multivariate analysis including the following factors as covariates: age, histology of endometrial cancer, myometrial invasion, and presence of endometriosis. We confirmed that the presence of concomitant endometriosis was the independent risk factor for SEOC (Table 3, p < 0.0001).

Almost all EAOCs accompanied with ECs were endometrioid carcinoma

Among the 21 patients with SEOCs, 18 had endometrioid cancer-related ECs (including three mixed cancers), and the remaining three had clear cell carcinoma (n = 1), serous carcinoma (n = 1), and mixed clear cell and serous carcinoma (n = 1) (Fig. 2A, Additional file 1: Table S1). Generally, EAOCs comprise clear cell and endometrioid ovarian carcinomas, and, in Japan, the incidence of clear cell carcinoma is higher than that of endometrioid carcinoma [23]. However, in our cohort, all of the EAOCs in EC patients with endometriosis were endometrioid carcinoma, and, even in those without endometriosis, endometrioid carcinoma was the most common histological type (Fig. 2B, C, the proportion of endometrioid carcinoma: 100% vs. 66%, p = 0.06).

Discussion

In the current study, we revealed that EC patients who have (concomitant) endometriosis have an increased risk of having SEOCs. In addition, although EAOCs comprise clear cell carcinoma and endometrioid carcinoma, almost all cases of SEOCs that were accompanied by endometriosis were endometrioid carcinoma.

Generally, patients with endometrioid carcinoma G1/G2 have a good prognosis compared to those with endometrioid G3 or other histological types. Although the proportion of endometrioid carcinoma G1/G2 in EC patients with endometriosis was higher than in those without it, there was no difference in prognosis between the two groups. It might be attributable to the high incidence of SEOC in EC patients with endometriosis because ovarian cancer generally has a worse prognosis than EC. In addition, despite the high prevalence of endometrioid carcinoma G1/G2, there is no difference in the frequency of lymph node metastasis. This suggests that patients with endometriosis may have a higher frequency of lymph node metastasis despite endometrioid carcinoma G1/G2.

A prevailing theory for the pathogenesis of endometriosis is the regurgitation of the uterine endometrium [2, 5, 24]. Accumulating evidence suggests that the uterine endometrium is the cell of origin for EAOCs [14]. Recently, in addition to the histopathological approaches, genomic approaches have been gaining attention as the diagnostic methods for SEOCs [25]. The latest genomic approaches based on next-generation sequencing showed clonal commonality between ovarian cancer and endometrial cancer in patients with SEOCs [25–29].

![Figure 1](image1.png)
Pathologically diagnosed SEOCs frequently have common oncogene mutations in ovarian and endometrial cancers [25, 26]. These lines of evidence support the hypothesis that endometriosis from the uterine endometrium with carcinogenic changes might be associated with the development of EAOCS and that additional carcinogenic changes might occur after transplantation outside the uterus (Fig. 3). Although EAOC is believed to be derived from endometriosis, the respective carcinogenic mechanisms of clear cell carcinoma and endometrioid carcinoma remain unknown. In the current study, we revealed that almost all SEOCs accompanied by endometriosis were of the endometrioid carcinoma-related type. This finding suggests that ovarian endometrioid carcinoma has a closer relationship with endometriosis from the abnormal uterine endometrium than with ovarian clear cell carcinoma.

It is noteworthy that one-fourth of the EC patients with endometriosis or half of those with ovarian endometrioma were accompanied by EAOC. Considering the high incidence of ovarian cancer in EC patients with endometriosis, treatment strategies should be carefully selected, such as laparotomy, minimally invasive surgeries, and ovary-preserving surgery. In particular, in the case of fertility-sparing therapies for EC patients with endometriosis, it is important to carefully examine endometriotic lesions together with the condition of the uterine endometrium. Atypical endometrial hyperplasia (AEMH) is sometimes accompanied by endometriosis. Ovaries are usually preserved during the treatment of patients with AEMH. However, considering the high probability of ovarian endometrioid carcinoma accompanied by abnormalities in the uterine endometrium, oophorectomy may be considered in patients with endometriosis accompanied by AEMH.

This study has several limitations. First, in the current study, we did not conduct a central pathological review. Therefore, the pathological diagnosis were based on the WHO classifications which were adopted at the time of diagnosis. In addition, the presence of endometriosis...
was reviewed using pathological reports from electronic medical records. However, some inconspicuous endometriotic lesions may have been overlooked. However, it is still notable that around half of EC patients with ovarian endometrioma have EAOC, and careful examination of the ovaries is necessary for these patients. Second, the diagnosis of SEOC is based on the histopathological diagnosis proposed by Scully and Young [22]. The criterion contains 12 features of SEOC, for example, there is no myometrial invasion or lymphovascular space invasion in endometrial cancer, and there is no ovarian cancer dissemination in the abdominal cavity. However, various investigators using these criteria sometimes arrive at different conclusions. In addition, considering the shared clonality between ovarian cancer and endometrial cancer in patients with SEOC, it might be difficult to accurately distinguish ovarian metastasis from SEOC, even with genomic analysis. To elucidate the pathogenesis of EAOCs, further research is warranted to investigate the molecular changes in pathologically normal uterine endometrium of patients with EAOCs. Third, there are ovarian endometrioid carcinomas that are not associated with ovarian endometriosis [30, 31]; therefore, the hypothesis that ovarian endometrioid carcinoma is arising from endometriosis from the abnormal uterine endometrium might be applied to only a part of ovarian endometrioid carcinomas. Further pathological and genomic analyses are needed to classify the pathogenesis of ovarian endometrioid carcinoma. Lastly, in the current study, we did not investigate the association between adenomyosis and EC. Because mutations in cancer-related genes are detected in adenomyosis [32], the presence of adenomyosis might affect the incidence of EC. Further research is warranted to elucidate the significance of adenomyosis in the development of EC.

Conclusion

In this study, we revealed that EC patients with endometriosis had a high probability of accompanying ovarian cancer and that ovarian endometrioid carcinoma was the most common histological type. For patients with endometriosis accompanied by abnormalities in the uterine endometrium, careful examination of endometriotic lesions may be important for the early detection of EAOCs.

Abbreviations

EAOC: Endometriosis-associated ovarian cancers; EC: Endometrial cancer; SEOC: Simultaneous endometrial and ovarian cancer; PFS: Progression-free survival; OS: Overall survival; AEMH: Atypical endometrial hyperplasia.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12905-022-01917-5.

Additional file 1: Fig. S1. Kaplan-Meier survival analysis of endometrial cancer patients. A Progression-free survival rate according to the presence of concomitant endometriosis. B Overall survival rate according to the presence of concomitant endometriosis. Log-rank test was used for p-values. Table S1. Pathological characteristics of SEOC cases.

Acknowledgements

The authors thank Mizuki Ikeda for his cooperation in creating illustrations. We would like to thank Editage (www.editage.com) for English language editing.

Author contributions

AT conceptualized the study, AI, MM, and AK obtained the data. AI and MM analyzed the data. AI, AT, TT, YM, MT, KS, MM, KK, and KO interpreted the data. MI and TU supervised pathological diagnosis. AI and AT wrote the original draft. TT, YM, MT, KS, MM, KK, KO, MI, TU, and YO reviewed and edited the manuscript. All authors reviewed the manuscript. KK, TU, KO, and YO supervised the study. All authors read and approved the final manuscript.

Funding

The study was self-funded by the authors.

Availability of data and materials

All data generated or analyzed during this study are available from the corresponding author, upon reasonable request.

Declarations

Ethical approval and consent to participate

This study was approved by the Research Ethics Committee of the Faculty of Medicine of the University of Tokyo. All methods were carried out in accordance with relevant guidelines and regulations. The Research Ethics Committee of the Faculty of Medicine of the University of Tokyo waived the requirement to obtain informed consent. This study was carried out by the opt-out method of our hospital website.

Consent for publication

Not applicable.

Competing interests

All authors have no conflicts of interest to disclose.

Author details

1Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 2Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 3Department of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Received: 22 May 2022 Accepted: 26 July 2022

Published online: 05 August 2022

References

1. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–99.
2. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927;14:422–69.
3. Pearce CJ, Templeman C, Rossing MA, Lee A, Nearn AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13:385–94.
4. Anglesio MS, Yong PJ. Endometriosis-associated Ovarian cancers. Clin Obstet Gynecol. 2017;60:711–27.
5. Zondervan KT, Becker CM, Koga K, Missmer SA, Taylor RN, Viganò P. Endometriosis. Nat Rev Dis Primers. 2018;4:9.
6. Murakami K, Kotani Y, Nakai H, Matsumura N. Endometriosis-associated Ovarian cancer: the origin and targeted therapy. Cancers (Basel). 2020;12:1676.
7. Melin A, Sperón P, Persson I, Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod. 2006;21:1237–42.
8. Thomsen LH, Schnack TH, Buchardi K, Hummelshøj L, Missmer SA, Forman A, et al. Risk factors of epithelial ovarian carcinomas among women with endometriosis: a systematic review. Acta Obstet Gynecol Scand. 2017;96:761–78.
9. Tanase Y, Furukawa N, Kobayashi H, Matsumoto T. Malignant transformation from endometriosis to atypical endometriosis and finally to endometrioid adenocarcinoma within 10 years. Case Rep Oncol. 2013;6:480–4.
10. Garavaglia E, Segismonti C, Ferrari S, Candidi M. The origin of endometriosis-associated ovarian cancer from uterine neoplastic lesions. Med Hypotheses. 2018;110:80–2.
11. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60:7052–6.
12. Anglesio MS, Papadopoulos N, Ayhan A, Nazerian TM, Noe M, Horlings HM, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med. 2017;376:1835–48.
13. Suda K, Nakaoka H, Yoshikura K, Ishiguro T, Tamura R, Mori Y, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep. 2018;24:1777–89.
14. Suda K, Cruz Diaz LA, Yoshikura K, Nakaoka H, Yachida N, Motoyama T, et al. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci. 2020;111:3000–9.
15. Ayhan A, Mao TL, Seekin T, Wu CH, Ganesan S, Ogawa H, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometrioid cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22:1310–5.
16. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532–43.
17. Yamamoto S, Tsuda H, Takano M, Iwaya K, Tami S, Matsubara O. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol. 2011;225:189–94.
18. Gounaris I, Charnock-Jones DS, Brenton JD. Ovarian clear cell carcinoma—bad endometriosis or bad endometrium? J Pathol. 2011;225:157–60.
19. Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, et al. Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. J Pathol. 2015;236:201–9.
20. Takeda T, Banjo K, Okawa R, Yanokura M, Irima M, Irie-Kunitomi H, et al. ARID1A-gene mutation in ovarian and endometrial cancers. Oncol Rep. 2016;35:607–13.
21. Sato M, Taguchi A, Fukui Y, Kawata A, Taguchi S, Kashiyama T, et al. Blood vessel invasion is a strong predictor of postoperative recurrence in endometrial cancer. Int J Gynecol Cancer. 2018;28:875–81.
22. Selvaggi SM. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Arch Pathol Lab Med. 2000;124:477–90.
23. Machida H, Matsuoka Y, Ebina Y, Kobayashi Y, Tabata T, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol. 2019;153:589–96.
24. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–75.
25. Ikeda Y, Oda K, Nakagawa S, Murayama-Hosokawa S, Yamamoto S, Ishikawa S, et al. Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. Int J Gynecol Cancer. 2012;22:725–31.
26. Schultheis AM, Ng CK, De Filippo MR, Piscuoglio S, Macedo GS, Gattuso S, et al. Massively parallel sequencing-based cloning analysis of synchronous endometrioid endometrial and Ovarian carcinomas. J Natl Cancer Inst. 2016;108:dv427.
27. Anglesio MS, Wang YK, Maassen M, Bashashati A, Senz J, et al. Synchronous endometrial and ovarian carcinomas: evidence of clonality. J Natl Cancer Inst. 2016;108(djv428.

28. Niskakoski A, Pasanen A, Pornika N, Eldfors S, Lassus H, Renkonen-Sinisalo L, et al. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: shared origin of synchronous carcinomas. Gynecol Oncol. 2018;150:92–8.

29. Reijnen C, Küsters-Vandevelde HVN, Ligtenberg MJL, Bulten J, Oosterwegel M, Snijders MPLM, et al. Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome. Int J Cancer. 2020;147:478–89.

30. Paik ES, Kim TJ, Choi CH, Kim BG, Bae DS, Lee JW. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018;29: e18.

31. Chen S, Li Y, Qian L, Deng S, Liu L, Xiao W, et al. A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer. Front Oncol. 2021;11: 668151.

32. Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, Kojima S, Takeyama R, Hashimoto T, Kyono T, Ikemura M, Taguchi A, Tanaka T, Tanaka Y, Sakata S, Takeuchi K, Muraoka A, Osuka S, Saito T, Oda K, Osuga Y, Terao Y, Kawazu M, Mano H. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10(1):5785.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.